Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

100%

9 of 9 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 1

4(36.4%)

Phase 2

3(27.3%)

Phase 3

3(27.3%)

Phase 4

1(9.1%)

11Total

Phase 1(4)

Phase 2(3)

Phase 3(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT04601233Phase 4Not Yet Recruiting

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

Role: collaborator

NCT04879589Phase 1Withdrawn

Phase 1 Study of ATRS-2002 in Healthy Male Adults

Role: collaborator

NCT02233751Phase 1Completed

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

Role: lead

NCT02504541Phase 3Completed

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

Role: lead

NCT02777242Phase 2Completed

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

Role: lead

NCT02159469Phase 3Completed

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

Role: lead

NCT01887418Phase 1Completed

Pharmacokinetic Study of Testosterone Enanthate

Role: lead

NCT00909181Phase 3Completed

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

Role: lead

NCT01618968Phase 2Completed

Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

Role: lead

NCT01618955Phase 2Completed

Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device

Role: lead

NCT01737944Phase 1Completed

Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration

Role: lead

All 11 trials loaded